Pharmacotherapy in Effort to Quit Smoking
Abstract
Nicotine dependence is a main role in tobacco dependence. Its physiological and psychological effect make smoker difficult to quit, making low success rate in smoking cessation. Combination of different method and continuity will increase smoking cessation success rate. Evidence shown that pharmacotherapy will increase success rate. Guideline’s for smoking cessation endorse physician to use first line pharmacotherapy, but it’s clinical application still limited. Physician should be aware about possibility for side effect. Some randomized controlled trial report major cardiovascular event in first line pharmacotherapy. Recent systematic review report no correlation between first line pharmacotherapy in smoking cessation and major cardiovascular event.Downloads
Download data is not yet available.
References
1. D’Souza MS, Markou A. Neuronal Mechanisms Underlying Development of Nicotine Dependence: Implications for Novel Smoking-Cessation Treatments. Addiction science & Clinical practice 2011.
2. Talhout R, Schulz T, Florek E, Benthem Jv, Wester P, Opperhuizen A. Hazardous Compounds in Tobacco Smoke. Int. J. Environ. Res. Public Health 2011;8:613-28.
3. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar. Jakarta: Kementrian Kesehatan RI, 2013:12.
4. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville: US Government Printing Office . 1990.
5. Sobieraj DM, White WB, Baker WL. Cardiovascular effect of pharmacologic Therapies for smoking cessation. J Am Soc Hypertens 2013;7(1):61-67.
6. Benowitz NL. Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. The American Journal of Medicine 2008;121 (4A):S3-10.
7. Giovino G, Henningfield J, Tomar S, Escobedo L, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995;17:48-65.
8. Lamberg L. Patients need more help to quit smoking: counseling and pharmacotherapy double success rate. . JAMA 2004;292:1286-90.
9. The Health Consequences of Smoking: Nicotine Addiction. Office of the Surgeon General. Washington, DC, 1988.
10. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362: 2295-303.
11. Fiore MC, jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update: US. Department of Health and Human Services, 2008.
12. Hughes J. An Algorithm for Choosing Among Smoking CessationTreatments. J Subst Abuse Treat 2008 June 34(4):426-32.
13. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tobacco Control 2009;18:34-42.
14. Curry SJ, Sporer AK, Pugach O, Campbell RT, Emery S. Use of tobacco cessation treatments among young adult smokers: 2005 national health interview survey. Am J Public Health 2007;97:1464-9.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000146.
16. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014:CD000031.
17. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database System Rev 2012(4):CD006103.
18. Shahab L, editor. Cost-effectiveness of pharmacotherapy for smoking cessation: National Centre for Smoking Cessation and Training (NCSCT), 2012.
19. Wiratmoko MR, Yunus F, Susanto AD, Ginting TT, Kekalih A. Efikasi Penggunaan Varenicline pada Program Berhenti Merokok Study Randomized Single Blind Clinical Trial placebo Controlled. Universitas Indonesia, 2012.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addictions 1991;86:1119-27.
21. Najem B, Houssiere A, Pathak A, Jassen C, Lemogoum D, Xhaet O, et al. Acut cardiovascular and synpathetic effect of nicotine replacement Therapy Hypertension 2006;47:1162-7.
22. Mundal HH, Hjemdal P, Ghesdal K. Acute effect of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men Eur J Clin Oharmacol 1995;41:411-6.
23. Tanus-Santos JE, Sampaio RC, Hyslop S, franchini KG, Moreno H. Endothelin ET(A) receptor antagonism attenuates the pressor effect of nicotine in rats. Eur J Pharmacol 2000;396:33-7.
24. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988;319:1318-30.
25. Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012;40:548-54.
26. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled,and open label trials. Am J Public Health 1999;89:1701-07.
27. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies A Network Meta-Analysis. Circulation 2014;129:28-41.
28. Fossati R, Apolone G, Negri E, Compagnoni A, LaVecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007;167:1791-97.
29. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-75.
30. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66.
31. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: Systematic review and meta-analysis. BMJ 2012;344:e2856.
2. Talhout R, Schulz T, Florek E, Benthem Jv, Wester P, Opperhuizen A. Hazardous Compounds in Tobacco Smoke. Int. J. Environ. Res. Public Health 2011;8:613-28.
3. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar. Jakarta: Kementrian Kesehatan RI, 2013:12.
4. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Rockville: US Government Printing Office . 1990.
5. Sobieraj DM, White WB, Baker WL. Cardiovascular effect of pharmacologic Therapies for smoking cessation. J Am Soc Hypertens 2013;7(1):61-67.
6. Benowitz NL. Neurobiology of Nicotine Addiction: Implications for Smoking Cessation Treatment. The American Journal of Medicine 2008;121 (4A):S3-10.
7. Giovino G, Henningfield J, Tomar S, Escobedo L, Slade J. Epidemiology of tobacco use and dependence. Epidemiol Rev 1995;17:48-65.
8. Lamberg L. Patients need more help to quit smoking: counseling and pharmacotherapy double success rate. . JAMA 2004;292:1286-90.
9. The Health Consequences of Smoking: Nicotine Addiction. Office of the Surgeon General. Washington, DC, 1988.
10. Benowitz NL. Nicotine addiction. N Engl J Med 2010;362: 2295-303.
11. Fiore MC, jaen CR, Baker TB, Bailey WC, Benowitz NL, Curry SJ, et al. Treating Tobacco Use and Dependence: 2008 Update: US. Department of Health and Human Services, 2008.
12. Hughes J. An Algorithm for Choosing Among Smoking CessationTreatments. J Subst Abuse Treat 2008 June 34(4):426-32.
13. Bader P, McDonald P, Selby P. An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts. Tobacco Control 2009;18:34-42.
14. Curry SJ, Sporer AK, Pugach O, Campbell RT, Emery S. Use of tobacco cessation treatments among young adult smokers: 2005 national health interview survey. Am J Public Health 2007;97:1464-9.
15. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000146.
16. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014:CD000031.
17. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database System Rev 2012(4):CD006103.
18. Shahab L, editor. Cost-effectiveness of pharmacotherapy for smoking cessation: National Centre for Smoking Cessation and Training (NCSCT), 2012.
19. Wiratmoko MR, Yunus F, Susanto AD, Ginting TT, Kekalih A. Efikasi Penggunaan Varenicline pada Program Berhenti Merokok Study Randomized Single Blind Clinical Trial placebo Controlled. Universitas Indonesia, 2012.
20. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addictions 1991;86:1119-27.
21. Najem B, Houssiere A, Pathak A, Jassen C, Lemogoum D, Xhaet O, et al. Acut cardiovascular and synpathetic effect of nicotine replacement Therapy Hypertension 2006;47:1162-7.
22. Mundal HH, Hjemdal P, Ghesdal K. Acute effect of low dose nicotine gum on platelet function in non-smoking hypertensive and normotensive men Eur J Clin Oharmacol 1995;41:411-6.
23. Tanus-Santos JE, Sampaio RC, Hyslop S, franchini KG, Moreno H. Endothelin ET(A) receptor antagonism attenuates the pressor effect of nicotine in rats. Eur J Pharmacol 2000;396:33-7.
24. Benowitz NL. Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med 1988;319:1318-30.
25. Tønnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012;40:548-54.
26. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled,and open label trials. Am J Public Health 1999;89:1701-07.
27. Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular Events Associated With Smoking Cessation Pharmacotherapies A Network Meta-Analysis. Circulation 2014;129:28-41.
28. Fossati R, Apolone G, Negri E, Compagnoni A, LaVecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. Arch Intern Med 2007;167:1791-97.
29. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-75.
30. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-66.
31. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: Systematic review and meta-analysis. BMJ 2012;344:e2856.
Published
2016-05-02
Views & Downloads
Abstract views: 3767
PDF downloads: 2627
PDF downloads: 2627
How to Cite
Ekawati, D., Radi, B., & Taufik, F. (2016). Pharmacotherapy in Effort to Quit Smoking. Indonesian Journal of Cardiology, 36(4), 220-6. https://doi.org/10.30701/ijc.v36i4.505
Section
Review Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
